Phase I of the CheckMate 143 trial (NCT02017717), which was the first to evaluate immune checkpoint inhibition with the first-line treatment of glioblastoma, showed that patients with unmethylated MGMT had similar overall survival with or without TMZ combined with nivolumab plus radiotherapy (100). This evidence concerns the gene MGMT and glioblastoma.